M&A / Deals Cancer biotech Parabilis books record IPO, raising $670m PharmaphorumParabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.OncologyRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide. Oncology Read full story Post navigation Previous: Alzecure enters collaboration and with Lilly for Alzheimer’s projectNext: Aditxt and Ignite announce merger plans with strategic partner Related Stories M&A / Deals Exegenesis Bio and Modalis sign research deal for Duchenne therapy pharminent September 11, 2026 M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026